IPC announces its official partnership with IFPA. Together we will work together to improve the lives of those living with psoriasis and psoriatic arthritis.
The U.S. Food and Drug Administration (FDA) has approved a second indication for SKYRIZI® (risankizumab-rzaa) to treat adults with active psoriatic arthritis.
The European Commission has approved SKYRIZI® for the treatment of active psoriatic arthritis in adults.
Stay informed Join the email list to receive the latest information on psoriasis meetings, manuscripts and research. SUBSCRIBE now available COVID-19 Psoriasis Resource Center Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve explore now IPC STATEMENT on SARS-CoV-2 Vaccines and Psoriasis Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients. READ FULL STATEMENT
Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve
Six key take-aways that physicians and other healthcare practitioners should consider when administering the SARS-CoV-2 vaccine to psoriasis patients.
READ FULL STATEMENT